Egfr
Entity.
- Evidence
- 124 documents · 49 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 12 Mar 2026, last seen 4 Nov 2026
- Measured
- 4% of mentions say something specific about it; the rest only name it
- As of
- 4 Nov 2026
Where this comes from
- an unnamed outlet · 2026-11-01 · Typ-1-Diabetes: Finerenon senkt eGFR bei 242 Erwachsenen zunächst leicht (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-27 · Case report and literature review: histologic transformation from EGFR-mutant lung adenocarcinoma to squamous cell carcinoma with newly detected SMAD4 and … (opens the source in a new tab)
- Endpoints News · 2026-10-26 · #ESMO26: SystImmune/BMS and Hengrui detail data in EGFR-mutant lung cancer (opens the source in a new tab)
- J Cancer Res Clin Oncol · 2026-10-20 · Combination of oral fluoropyrimidines and EGFR-directed antibodies in frail patients with metastatic colorectal cancer: a systematic review. (opens the source in a new tab)
- bioRxiv Cancer Biology · 2026-10-20 · A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers (opens the source in a new tab)
- Neoplasma · 2026-10-14 · ctDNA retesting to guide anti-EGFR therapy in later-line metastatic colorectal cancer. (opens the source in a new tab)
- Oncologist · 2026-10-03 · REVERCE II: A Phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer. (opens the source in a new tab)
- Gan To Kagaku Ryoho · 2026-10-01 · Optimal Duration of Preventive Minocycline Administration for Skin-Related Adverse Events Induced by Anti-EGFR Antibodies in Metastatic Colorectal Cancer (opens the source in a new tab)
- Crc-Digest · 2026-09-27 · Pharmacist-Led Skin Toxicity Management for Anti-EGFR Therapy (opens the source in a new tab)
- Crc-Digest · 2026-09-26 · Inflammation markers predict outcomes in RAS/BRAF wild-type mCRC on anti-EGFR therapy (opens the source in a new tab)
- Crc-Digest · 2026-09-26 · Circulating tumor DNA tumor fraction predicts anti-EGFR rechallenge response (opens the source in a new tab)